Navigation Links
Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S.
Date:3/28/2008

MORRISTOWN, N.J., March 28 /PRNewswire/ -. Actavis Group, the international generic pharmaceuticals company, today announced that it has received two separate approvals from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (SR). Distribution of the products will commence immediately.

Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Wellbutrin SR(R) and are indicated for the treatment of major depressive disorder. Annual sales of brand and generic Wellbutrin SR(R) were US$ 498 million for the 12 months ending December 2007 according to IMS Health data.

Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Zyban(R) and are indicated as an aid to smoking cessation treatment. Annual sales of brand and generic Zyban(R) were US$ 12 million for the 12 months ending December 2007 according to IMS Health data.

Commenting on the new approvals, Terry Fullem, Vice President of Marketing and Portfolio in the U.S. said:

"These approvals further enhance our strength in the area of modified release products and provide valuable options to our customers and patients."

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at http://www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesse
'/>"/>

SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
2. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
3. Seneca Valley High School Student Receives Science Award From MedImmune
4. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
5. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
6. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
7. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
8. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
9. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
10. Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL
11. Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... ERT (Nasdaq: ERES ), a leading provider of ... biopharmaceutical, medical device, and related industries, announced today that it ... Thursday, October 29, 2009 after the market closes. After the ... PM EDT that day. , For the conference call, ...
... A faster tool for cell programming and a new ... grand prizes of the 2009 Collegiate Inventors Competition, a program ... Abbott Fund, the non-profit foundation of the global health care ... (USPTO). Harris Wang, who invented a new way of ...
... 21 BioWa, Inc. (BioWa) and NKT Therapeutics, ... into an agreement which provides NKTT with access ... development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. ... research, develop, manufacture and commercialize antibodies targeting natural ...
Cached Biology Technology:ERT to Announce 2009 Third Quarter Results on October 29, 2009 2Winners Announced in 2009 Collegiate Inventors Competition(R) 2Winners Announced in 2009 Collegiate Inventors Competition(R) 3Winners Announced in 2009 Collegiate Inventors Competition(R) 4Winners Announced in 2009 Collegiate Inventors Competition(R) 5Winners Announced in 2009 Collegiate Inventors Competition(R) 6Winners Announced in 2009 Collegiate Inventors Competition(R) 7BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 2BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 3
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
(Date:4/17/2014)... many serious conditions such as heart disease, epilepsy and ... therapies. Unfortunately, there is still much scientists do not ... and unexpected insight into the structure of sodium channels ... - which are responsible for ,fine-tuning, the activity of ... recent edition of the Journal of Biological Chemistry ...
(Date:4/17/2014)... Ind. -- Indiana University researchers have detected new early-warning ... diabetes. This discovery could have far-reaching implications for the ... care of over 25 million Americans. , "We had ... retinas at such early stages," said Ann Elsner, professor ... and lead author of the study. "We set out ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Structure of sodium channels different than previously believed 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... a commercially viable method for mass producing effective vaccines ... the months required for traditional egg-based vaccines. They report ... , The next flu pandemic could happen any time," ... (PSC) and a researcher on the study. "The ...
... click as Cornell University researchers have fabricated a set ... receptors on cell membranes and trigger larger-scale responses within ... an allergic response. , How cell membranes control cellular ... However, nanotechnology now gives researchers new tools to understand ...
... Not all biological weapons are created equal. They are ... agents being the scariest: They are easy to spread, ... pubic health system. One of these worrisome organisms is ... media attention. But work in Vince Fischetti's laboratory at ...
Cached Biology News:New influenza vaccine takes weeks to mass produce 2'Nano-keys' bind cell receptors and trigger allergic reactions 2'Nano-keys' bind cell receptors and trigger allergic reactions 3Newly discovered protein kills anthrax bacteria by exploding their cell walls 2
... Avian Myeloblastosis Virus Reverse Transcriptase (AMV RT) ... DNA, RNA or RNA:DNA hybrids (1). It ... efficient than RNA primers) as well as ... intrinsic RNase H activity. Both nonionic detergents ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... is a preparation of deoxyribonuclease I ... to produce 3-hydroxyl oligonucleotides. This preparation ... where maintaining the integrity of RNA ... for use with the Core Footprinting ...
... Liquid. In 100 mM KCl, 20 ... 20% glycerol, pH 7.9. AVOID FREEZE/THAW CYCLES. Human ... protein of 765 amino acids encoded by a ... positive and negative supercoiled DNAs without the requirement ...
Biology Products: